```
Db        298 CTCTTTATGCCACGTGAGGATACAGCAAGGCCCCAATCTGCAAGCCAGGAAGAGTCGTCA 239

Qy        121 CGAGAACCAGACCATGCAGGAACTCTGATCGTGGACATTTCAACCTCCAGAACTGTGATC 180

Db        238 CGAGAACCAGACCATGCAGGAACTCTGATCGTGGACATTTCAACCTCCAGAACTGTGATC 179

Qy        181 CAAAATGCATATGTATCTTTGGAAGAAACTCTGAAGTAAAGGCCGGAATATTCTTTGTTT 240

Db        178 CAAAATGCATATGTATCTTTGGAAGAAACTCTGAAGTAAAGGCCGGAATATTCTTTGTTT 119

Qy        241 AAAACATTAAAAACAAAACAGACCAAAGCATCAAGCAAGAAGTTTCCTGGCAATAAACTA 300

Db        118 AAAACATTAAAAACAAAACAGACCAAAGCATCAAGCAAGAAGTTTCCTGGCAATAAACTA 59

Qy        301 AGCACAGCATTATTTTTTAAGGAACACAAATTAAGTGTTCAACCTGTGGCAAATTTGT 358

Db         58 AGCACAGCATTATTTTTTAAGGAACACAAATTAAGTGTTCAACCTGTGGCAAATTTGT 1
```

RESULT 4
ABN96147/c
ID ABN96147 standard; DNA; 176 BP.
XX
AC ABN96147;
XX
DT 13-AUG-2002 (first entry)
XX
DE Gene #2645 used to diagnose liver cancer.
XX
KW Gene; liver cancer; ds; hepatocellular carcinoma; hepatotropic;
KW metastatic liver tumour; cytostatic; expression profile; disease state;
KW disease progression; drug toxicity; drug efficacy; drug metabolism.
XX
OS Homo sapiens.
XX
PN WO200229103-A2.
XX
PD 11-APR-2002.
XX
PF 02-OCT-2001; 2001WO-US030589.
XX
PR 02-OCT-2000; 2000US-0237054P.
XX
PA (GENE-) GENE LOGIC INC.
XX
PI Horne D, Alvares C, Peres-Da-Silva S, Vockley JG;
XX
DR WPI; 2002-426119/45.
XX
PT Diagnosing and detecting the progression of liver cancer, hepatocellular
PT carcinoma or metastatic liver tumor in a patient, involves detecting the
PT level of expression of two or more genes in a liver tissue sample.
XX
PS Claim 1; SEQ ID NO 2645; 298pp; English.
XX
CC The invention relates to a novel method for diagnosing and detecting the
CC progression of liver cancer, hepatocellular carcinoma or metastatic liver
CC tumour in a patient, and differentiating metastatic liver cancer from
CC hepatocellular carcinoma in a patient, involving detecting the level of
CC expression of two or more genes represented in ABN93503-ABN97455 in a
CC tissue sample. The method of the invention has hepatotropic, and
CC cytostatic activity. The method is useful for diagnosing and detecting
CC the progression of liver cancer, hepatocellular carcinoma and metastatic
CC liver carcinoma in a patient. The method is useful for identifying
CC expression profiles which serve as useful diagnostic markers as well as
CC markers that can be used to monitor disease states, disease progression,
CC drug toxicity, drug efficacy and drug metabolism. Note: The sequence data
CC for this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 176 BP; 54 A; 23 C; 23 G; 75 T; 0 U; 1 Other;

  Query Match   30.7%; Score 148.4; DB 6; Length 176;
  Best Local Similarity   95.6%; Pred. No. 1.6e-17;

Matches 152; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

```
Qy        310 TTATTTTTAAGGAACACAAATTAAGTGTTCAACCTGTGGCAAATTTGTACTTTCTCCCT 369
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        176 TTATTTTTAAGGAACACAAATTAAGTGTTCAACCTGTGGCAAATTTGTACTTTCTCCCT 117

Qy        370 GAATTATGTTGTTATCAAAGAAAAAAAATTGGGAAGCATGGCAAAATATCATCAAAACTGA 429
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        116 GAATTATGTTGTTATCAAAGAAAAAAAATTGGGAAGCATGGCAAAATATCATCAAAACTGA 57

Qy        430 AACTAGAATTAAACTAAATTAAAATAAAAAAAAAAAAAA 468
              |||||||||||||  || |||| |||||  ||| ||||
Db         56 AACTAGAATTAAACANAACTAAATTAAAATGAAATAAAA 18
```

RESULT 5
ABL33696/c
ID ABL33696 standard; DNA; 6668 BP.
XX
AC ABL33696;
XX
DT 26-MAR-2002 (first entry)
XX
DE Human immune system associated gene SEQ ID NO: 1669.
XX
KW Human; immune system disease; cytosine methylation; antiasthmatic;
KW antiarteriosclerotic; antianaemic; cytostatic; nootropic;
KW neuroprotective; anti-HIV; anticonvulsant; ophthalmological;
KW antirheumatic; antiarthritic; antidiabetic; antipsoriatic;
KW antiinflammatory; cancer; eye disease; arteriosclerosis; anaemia;
KW acute myeloid leukaemia; Alzheimer's disease; AIDS; epilepsy;
KW neurofibromatosis; rheumatoid arthritis; psoriasis; bowel disease; gene;
KW ds.
XX
OS Homo sapiens.
XX
PN WO200200928-A2.
XX
PD 03-JAN-2002.
XX
PF 02-JUL-2001; 2001WO-EP007537.
XX
PR 30-JUN-2000; 2000DE-01032529.
PR 01-SEP-2000; 2000DE-01043826.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2002-130909/17.
XX
PT Nucleic acid comprising fragment of chemically modified gene, useful for
PT diagnosis and treatment of diseases associated with abnormal cytosine
PT methylation.
XX
PS Claim 1; SEQ ID NO 1669; 32pp + Sequence Listing; German.
XX
CC The present invention provides a number of human immune system associated
CC genes which are modified by the methylation of cytosines. The sequences
CC can be used in the diagnosis and treatment of immune system disorders,
CC including eye diseases such as retinopathy, neovascular glaucoma and
CC macular degeneration, arteriosclerosis, anaemia, cancer, acute myeloid
CC leukaemia, Alzheimer's disease, AIDS, epilepsy, neurofibromatosis,
CC rheumatoid arthritis, psoriasis and inflammatory/ulcerative bowel
CC diseases. The present sequence is a gene of the invention
XX
SQ Sequence 6668 BP; 1628 A; 328 C; 1974 G; 2737 T; 0 U; 1 Other;

Query Match 15.2%; Score 73.4; DB 6; Length 6668;
Best Local Similarity 51.7%; Pred. No. 0.00041;
Matches 167; Conservative 0; Mismatches 156; Indels 0; Gaps 0;

```
Qy        162 AACCTCCAGAACTGTGATCCAAAATGCATATGTATCTTTGGAAGAAACTCTGAAGTAAAG 221
              |||  |  |||  | |  |||||  ||||  | |     || ||      ||  |||
Db       5831 AACATAAATAACGATAAATTAAAATATATATAAAACACAAAAAAAAAAAAAACAAACAAAA 5772
```